Nanoviricides (NNVC) Cash from Operations (2010 - 2026)

Nanoviricides has disclosed Cash from Operations across 17 years of filings, most recently posting -$2.0 million for Q1 2026.

• In Q1 2026, Cash from Operations rose 1.73% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$7.3 million (up 11.32% YoY), while the FY2025 annual figure was -$8.5 million, down 34.59% from the prior year.
• Cash from Operations came in at -$2.0 million for Q1 2026 at Nanoviricides, up from -$2.0 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$1.0 million in Q3 2022 to a low of -$2.6 million in Q3 2024.
• Average Cash from Operations over 5 years is -$1.7 million, with a median of -$1.7 million recorded in 2023.
• Year-over-year, Cash from Operations plunged 121.46% in 2024 and soared 38.34% in 2025.
• Over 5 years, Cash from Operations stood at -$1.4 million in 2022, then retreated by 22.74% to -$1.7 million in 2023, then slipped by 27.46% to -$2.2 million in 2024, then advanced by 6.73% to -$2.0 million in 2025, then rose by 4.26% to -$2.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$2.0 million in Q1 2026, -$2.0 million in Q4 2025, and -$1.6 million in Q3 2025.